Assignee
ARAXES PHARMA LLC
US·46 granted patents·13 pending applications·919 citations·filing 2014–2024
Top patents by PatentIndex Score
59 records- 0198US10144724B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Dec 4, 2018·44 cites·42 claims
- 0298US9810690B2Method for screening inhibitors of RasARAXES PHARMA LLC·Filed 2016·Granted Nov 7, 2017·41 cites·30 claims
- 0397US10745385B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2018·Granted Aug 18, 2020·17 cites·54 claims
- 0497US10646488B2Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereofARAXES PHARMA LLC·Filed 2017·Granted May 12, 2020·22 cites·16 claims
- 0597US10377743B2Inhibitors of RAS and methods of use thereofARAXES PHARMA LLC·Filed 2017·Granted Aug 13, 2019·29 cites·31 claims
- 0697US10370386B2Substituted quinolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2017·Granted Aug 6, 2019·33 cites·30 claims
- 0797US10351550B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 16, 2019·27 cites·32 claims
- 0897US10246424B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Apr 2, 2019·36 cites·90 claims
- 0997US9988357B2Methods for preparation of quinazoline derivativesARAXES PHARMA LLC·Filed 2016·Granted Jun 5, 2018·38 cites·32 claims
- 1097US9926267B2Covalent inhibitors of K-Ras G12CARAXES PHARMA LLC·Filed 2015·Granted Mar 27, 2018·38 cites·35 claims
- 1197US9862701B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2015·Granted Jan 9, 2018·45 cites·18 claims
- 1297US9840516B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2014·Granted Dec 12, 2017·73 cites·33 claims
- 1397US9745319B2Irreversible covalent inhibitors of the GTPase K-Ras G12CARAXES PHARMA LLC·Filed 2014·Granted Aug 29, 2017·43 cites·11 claims
- 1497US9227978B2Covalent inhibitors of Kras G12CARAXES PHARMA LLC·Filed 2014·Granted Jan 5, 2016·47 cites·24 claims
- 1596US10927125B2Substituted cinnolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 23, 2021·11 cites·29 claims
- 1696US10919850B2Covalent inhibitors of KRas G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 16, 2021·9 cites·38 claims
- 1796US10858343B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 8, 2020·11 cites·15 claims
- 1896US10829458B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Nov 10, 2020·13 cites·29 claims
- 1996US10730867B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Aug 4, 2020·15 cites·19 claims
- 2096US10723738B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2019·Granted Jul 28, 2020·15 cites·22 claims
- 2196US10689356B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jun 23, 2020·16 cites·15 claims
- 2296US10414757B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Sep 17, 2019·33 cites·49 claims
- 2396US10280172B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2017·Granted May 7, 2019·34 cites·19 claims
- 2496US10273207B2Covalent inhibitors of kras G12CARAXES PHARMA LLC·Filed 2018·Granted Apr 30, 2019·24 cites·34 claims
- 2595US10736897B2Compounds and methods of use thereof for treatment of cancerARAXES PHARMA LLC·Filed 2018·Granted Aug 11, 2020·28 cites·15 claims
- 2695US10428064B2Fused-tricyclic inhibitors of KRAS and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Oct 1, 2019·27 cites·28 claims
- 2795US10111874B2Combination therapies for treatment of cancerARAXES PHARMA LLC·Filed 2015·Granted Oct 30, 2018·39 cites·20 claims
- 2895US10011600B2Methods and compositions for inhibition of RasARAXES PHARMA LLC·Filed 2015·Granted Jul 3, 2018·12 cites·21 claims
- 2994US11878985B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2020·Granted Jan 23, 2024·2 cites·43 claims
- 3094US11377441B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2020·Granted Jul 5, 2022·3 cites·28 claims
- 3194US11021470B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Jun 1, 2021·8 cites·21 claims
- 3294US10882847B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jan 5, 2021·11 cites·23 claims
- 3394US10875842B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 29, 2020·11 cites·20 claims
- 3493US11059819B2Fused hetero-hetero bicyclic compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 13, 2021·8 cites·20 claims
- 3593US10975071B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Apr 13, 2021·9 cites·20 claims
- 3693US10822312B2Substituted quinazoline compounds and methods of useARAXES PHARMA LLC·Filed 2017·Granted Nov 3, 2020·10 cites·12 claims
- 3793US10647703B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted May 12, 2020·18 cites·13 claims
- 3889US11279689B21-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancerARAXES PHARMA LLC·Filed 2018·Granted Mar 22, 2022·4 cites·13 claims
- 3989US11136308B2Substituted quinazoline and quinazolinone compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Oct 5, 2021·5 cites·26 claims
- 4088US11274093B2Fused bicyclic benzoheteroaromatic compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Mar 15, 2022·4 cites·16 claims
- 4188US2024352028A1Substituted quinazolines as inhibitors of kras g12cARAXES PHARMA LLC·Filed 2024·Application pending·0 cites
- 4287US11358959B2Benzothiophene and benzothiazole compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jun 14, 2022·4 cites·20 claims
- 4384US2025154133A1Covalent inhibitors of krasARAXES PHARMA LLC·Filed 2024·Application pending·0 cites
- 4484US2024043441A1Inhibitors of kras g12cARAXES PHARMA LLC·Filed 2023·Application pending·0 cites
- 4584US2023303586A1Inhibitors of kras g12cARAXES PHARMA LLC·Filed 2023·Application pending·0 cites
- 4683USRE50527ECovalent inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2023·Granted Aug 12, 2025·0 cites·41 claims
- 4781US12234244B2Substituted piperazines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2022·Granted Feb 25, 2025·0 cites·12 claims
- 4880USRE50490ESubstituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2022·Granted Jul 15, 2025·0 cites·29 claims
- 4977US11639346B2Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRASARAXES PHARMA LLC·Filed 2018·Granted May 2, 2023·2 cites·25 claims
- 5076US2023203018A1Covalent inhibitors of krasARAXES PHARMA LLC·Filed 2022·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →